NGVT Ingevity Corp
Chemicals & Allied Products · NYSE · SEC CIK 1653477 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-3.7%
TTM net income YoY190.7%
TTM EPS YoY196.1%
Revenue 3-yr CAGR-12.7%
Net income 3-yr CAGR-22.2%
Margins
Gross margin42.0%
Operating margin—
Net margin5.3%
FCF margin10.8%
EBITDA margin—
Returns
ROE59.5%
ROA3.6%
ROIC (approx.)—
Asset turnover0.68x
Leverage & solvency
Liabilities / assets95.8%
Debt / equity18.18x
Current ratio1.48x
Interest coverage—
Cash quality & payout
Operating cash flow / net income3.02x
Accruals ratio-7.2%
Payout ratio—
Capex / revenue5.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $1.17B | $1.20B |
| Cost of revenue | $706.10M | $735.30M |
| Gross profit | $461.50M | $464.80M |
| R&D expense | $28.40M | $24.50M |
| SG&A expense | $171.20M | $157.80M |
| Operating income | $418.70M | $425.90M |
| Interest expense | $78.30M | $97.80M |
| Pretax income | -$142.10M | -$140.50M |
| Income tax | $8.20M | -$19.10M |
| Net income | -$167.10M | -$430.30M |
| EBITDA | $525.10M | $534.20M |
| EPS (basic) | -4.61 | -11.85 |
| EPS (diluted) | -4.61 | -11.85 |
| Weighted avg. shares (diluted) | 36.22M | 36.32M |
| Balance sheet | ||
| Cash & equivalents | $78.10M | $68.00M |
| Inventory | $186.00M | $195.90M |
| Current assets | $454.20M | $493.20M |
| PP&E, net | $608.10M | $642.90M |
| Goodwill | $4.30M | $175.20M |
| Intangibles | $176.10M | $278.80M |
| Total assets | $1.65B | $2.02B |
| Current liabilities | $341.30M | $264.10M |
| Short-term debt | $47.10M | $61.30M |
| Long-term debt | $1.16B | $1.34B |
| Total debt | $1.21B | $1.40B |
| Total liabilities | $1.62B | $1.83B |
| Shareholders' equity | $29.70M | $195.20M |
| Net debt | $1.13B | $1.33B |
| Shares outstanding | 35.49M | 36.35M |
| Cash flow statement | ||
| Operating cash flow | $331.20M | $128.60M |
| Capital expenditure | $57.70M | $77.60M |
| Free cash flow | $273.50M | $51.00M |
| Investing cash flow | -$57.50M | -$79.50M |
| Financing cash flow | -$252.20M | -$70.20M |
| Depreciation & amortization | $106.40M | $108.30M |
| Stock-based compensation | $18.30M | $11.90M |
| Share buybacks | $56.30M | $0 |
Free plan shows the latest 2 periods; Pro shows all 12 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.